Clik here to view.
Human Space Travel as a Platform to Accelerate Biomedical Innovation
A manned mission to Mars is slated for as early as 2024, but there are serious health risks that must be mitigated in order for such a mission to be successful. The most pressing risk identified by...
View ArticleClik here to view.
San Antonio Develops “Action Plan” to Draw Life Sciences Businesses
San Antonio — San Antonio has a new “action plan” for bringing more life sciences businesses and professionals to the city, as well as for retaining those it already has.Economic development groups and...
View ArticleClik here to view.
Hypergiant in Space, Celltex & Saudi, Siete Foods’ $90M, & More TX Tech
Let’s catch up on the latest innovation news in Texas.—Aeglea Biotherapeutics, an Austin biotech, raised $60 million in a secondary public stock offering Wednesday, according to a press release. The...
View ArticleClik here to view.
GenCure Plans Adult Stem Cell Lab at San Antonio “Innovation Center”
San Antonio—GenCure, a subsidiary of life sciences nonprofit BioBridge Global, expects to open a biomanufacturing laboratory this year at a new “innovation center” that’s being developed by VelocityTX...
View ArticleClik here to view.
Bio Roundup: Golumbeski’s Legacy, CRISPR Moratorium, Rebate Week & More
While all eyes in the biopharmaceutical world are currently trained on Bristol-Myers Squibb’s proposal to buy Celgene for $74 billion, it wasn’t that long ago that another company’s gaze was fixed on...
View ArticleClik here to view.
InGeneron Adds $23M to Test Stem Cell Therapy for Rotator Cuff Tears
Houston — Stem-cell technology developer InGeneron has added another $23 million to a Series D financing it announced in 2017, bringing the total of the funding round to $43 million.Based in Houston,...
View ArticleClik here to view.
Skyhawk Inks Deal With Genentech for Cancer and Neuro Drug Discovery
Skyhawk Therapeutics has added Genentech to the growing list of companies it’s working with to find new drugs.The deal with Genentech, a Roche subsidiary, calls for Cambridge, MA-based Skyhawk to use...
View ArticleClik here to view.
Trefoil Therapeutics Raises $28M and Eyes the Clinic for Cornea Drug
Trefoil Therapeutics, which is developing treatments for diseases that affect the cornea, the outermost layer of the eye, has raised $28 million to move its lead drug candidate into human testing.The...
View ArticleClik here to view.
San Antonio to Honor Regenerative Medicine Pioneer Stephen Badylak
San Antonio — Ah, to be able to regrow a missing limb like a slimy salamander—a trick long dreamed of by youngsters and scientists alike.Research into such regenerative abilities has increasingly...
View ArticleClik here to view.
Organovo Halts Liver Tissue R&D, Plans Restructuring to Cut Costs
Organovo says it has run out of money to advance its efforts to develop 3-D “patches” of living human liver tissue to tide over people waiting for an organ transplant.The San Diego-based biotech has...
View ArticleClik here to view.
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds
Hearing loss affects millions of Americans but to date, there are no FDA-approved medicines to treat them. Frequency Therapeutics is developing a hearing loss drug that taps into the body’s...
View ArticleClik here to view.
Viscient Bio Proposes Organovo Merger to Tackle NASH and Go Beyond
[Updated 5:58 p.m. PT. See below.] Organovo, a company developing technology to 3D print human tissue, announced two months ago that its dwindling cash is leading it to explore options that include...
View ArticleClik here to view.
With $65M, Cygnal Tunes In to Nerve Signals for Drug-Making Clues
The peripheral nervous system traverses the body, connecting the brain and spinal cord to distant organs and limbs similar to the way a fiber optic network connects an Internet provider to a computer...
View ArticleClik here to view.
Stryker Adds to Trauma & Extremities Biz With $4B Wright Medical Deal
Medical device giant Stryker is strengthening its presence in trauma and extremities surgeries with a cash deal to acquire Wright Medical for $4 billion.According to deal terms announced Monday,...
View ArticleClik here to view.
Bio Roundup: Feds Sue Gilead, Biogen Eyes China, CRISPR’d Kidneys & More
During the state of the union address this year, President Trump pledged to end HIV transmission within the next decade. A key part of that plan is an HIV prevention drug made by Gilead Sciences. That...
View ArticleClik here to view.
Histogen, Timber Pharma Plan Reverse Mergers to Join Public Markets
Two privately held biotechs on Tuesday announced plans for reverse mergers, transactions that provide a faster route to go public than a conventional IPO and also give struggling public companies a...
View ArticleClik here to view.
Decibel Therapeutics Strikes a Balance, Adding Regenerative Med Focus
Decibel Therapeutics emerged four years ago aiming to build a pipeline of medicines for various forms of hearing loss. One of those drugs is in the clinic. Others were shelved. And some of the...
View ArticleClik here to view.
War Paint to Bone Paint: MIT Spinout Aims to Transform Regenerative Meds
Driven by 20 years in the military, the founder of Theradaptive hopes his firm’s regenerative “paint” technology platform can transform bone repair, spinal fusion, and sports medicine.The firm, spun...
View ArticleClik here to view.
Bio Roundup: A Royal IPO, Akili Arrives, Orca Bio Surfaces & More
The biggest life sciences deal this week involves a company that doesn’t discover or develop drugs, or even sell them. Yet its mark is found on pharmaceutical products spanning the entire...
View ArticleClik here to view.
Advisory Body Backs MesoBlast Therapy for Transplant Complication
An FDA advisory committee Thursday voted 9-1 to recommend that the agency approve a stem cell therapy developed by MesoBlast as a treatment for acute graft-versus-host disease (aGVHD) in children. The...
View Article